OTCM
BIEI
Market cap499kUSD
Aug 08, Last price
0.00USD
1D
-16.67%
1Q
25.00%
Jan 2017
-90.00%
IPO
-99.95%
Name
Premier Biomedical Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
215.68%
Rev. gr., 5y
-37.00%
Revenues
0k
Net income
-202k
L+310.42%
CFO
-171k
L
Profile
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1 | ||||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1) | ||||||||
NOPBT Margin | |||||||||
Operating Taxes | (168) | 3 | |||||||
Tax Rate | |||||||||
NOPAT | 168 | (1) | |||||||
Net income | (202) 310.42% | (49) 27.05% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 175 | ||||||||
BB yield | -17.72% | ||||||||
| Debt | |||||||||
Debt current | 568 | 437 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 564 | 437 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (171) | 3 | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 175 | ||||||||
FCF | 239 | 28 | |||||||
| Balance | |||||||||
Cash | 4 | ||||||||
Long term investments | |||||||||
Excess cash | 4 | ||||||||
Stockholders' equity | (17,853) | (17,650) | |||||||
Invested Capital | 15,939 | 15,807 | |||||||
ROIC | 1.06% | ||||||||
ROCE | 0.08% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 1,098,880 | 1,098,880 | |||||||
Price | 0.00 -79.55% | 0.00 31.34% | |||||||
Market cap | 989 -79.55% | 4,835 44.33% | |||||||
EV | 1,555 | 5,275 | |||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | 31 | 31 | |||||||
Interest/NOPBT | |||||||||